MIM
CELG

MetLife Investment Management’s Celgene Corp CELG Stock Holding History

MetLife Investment Management’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-192,874
Closed -$19.2M – 2390
2019
Q3 		$19.2M Sell
192,874
-1,523
-0.8% -$145K 0.21% 86
2019
Q2 		$18M Sell
194,397
-5,255
-3% -$499K 0.19% 96
2019
Q1 		$18.8M Sell
199,652
-324
-0.2% -$28.3K 0.2% 92
2018
Q4 		$12.8M Sell
199,976
-4,634
-2% -$342K 0.16% 120
2018
Q3 		$18.3M Sell
204,610
-3,467
-2% -$306K 0.19% 95
2018
Q2 		$16.5M Sell
208,077
-18,282
-8% -$1.52M 0.2% 91
2018
Q1 		$20.2M Sell
226,359
-17,243
-7% -$1.66M 0.24% 75
2017
Q4 		$25.4M Buy
+243,602
New +$27.5M 0.29% 60

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $8.4B AUM 51.89% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return

MetLife Investment Management's CELG Position: Q4 2019 in Review

MetLife Investment Management sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 192,874 shares — an estimated $19.2M sold.

MetLife Investment Management first reported a position in CELG in Q4 2017 and held it in 8 quarters. The position peaked at $25.4M in Q4 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • MetLife Investment Management reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • MetLife Investment Management sold 192,874 Celgene Corp shares in Q4 2019, an estimated $19.2M.
  • MetLife Investment Management first reported a position in Celgene Corp in Q4 2017 and held it in 8 quarters.
  • MetLife Investment Management's Celgene Corp position peaked at $25.4M in Q4 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on MetLife Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.